Literature DB >> 27686169

Laboratory Investigation of Myeloproliferative Neoplasms (MPNs):  Recommendations of the Canadian Mpn Group.

Lambert Busque1, Anna Porwit2, Radmila Day3, Harold J Olney4, Brian Leber5, Vincent Éthier6, Shireen Sirhan7, Linda Foltz8, Jaroslav Prchal9, Suzanne Kamel-Reid2, Aly Karsan10, Vikas Gupta11.   

Abstract

OBJECTIVES: To standardize diagnostic investigations for myeloproliferative neoplasms (MPNs) to increase homogeneity in patient care and to streamline diagnostic approaches in the most efficient and cost-effective manner.
METHODS: The development of Canadian expert consensus recommendations for the diagnosis of MPNs began with a review of the following: clinical evidence, daily practice, existing treatment guidelines, and availability of diagnostic tools. Each group member was assigned a specific topic, which they discussed with the entire group during several consensus meetings.
RESULTS: This document provides the Canadian MPN group's recommendations, proposed diagnostic algorithms, and background evidence upon which decisions were made.
CONCLUSIONS: Standardization of diagnostic investigations will increase homogeneity in patient care and provide a foundation for future clinical research in this rapidly evolving therapeutic area. Streamlining diagnostic approaches in the most efficient and cost-effective manner will also result in significant cost saving for the health care system. © American Society for Clinical Pathology, 2016. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  BCR-ABL negative; CALR; Essential thrombocythemia; JAK2 V617F; MPL; Myelofibrosis; Myeloproliferative neoplasms; Polycythemia vera

Mesh:

Year:  2016        PMID: 27686169     DOI: 10.1093/ajcp/aqw131

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  10 in total

Review 1.  Investigation and management of erythrocytosis.

Authors:  Siraj Mithoowani; Marissa Laureano; Mark A Crowther; Christopher M Hillis
Journal:  CMAJ       Date:  2020-08-10       Impact factor: 8.262

2.  Beyond Hemoglobin: When and How to Work Up Possible Polycythemia Vera.

Authors:  Gene Shaw; Richard Berg
Journal:  Clin Med Res       Date:  2019-10-03

Review 3.  The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.

Authors:  Tiziano Barbui; Jürgen Thiele; Heinz Gisslinger; Hans Michael Kvasnicka; Alessandro M Vannucchi; Paola Guglielmelli; Attilio Orazi; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2018-02-09       Impact factor: 11.037

4.  Retrospective Study of High Hemoglobin Levels in 56 Young Adults.

Authors:  Alexandra Desnoyers; Michel Pavic; Paul-Michel Houle; Jean-Francois Castilloux; Patrice Beauregard; Line Delisle; Richard Le Blanc; Jean Dufresne; Josie-Anne Boisjoly; Vincent Ethier
Journal:  J Hematol       Date:  2018-05-10

5.  Development and validation of a sequential two-step algorithm for the screening of individuals with potential polycythaemia vera.

Authors:  Miguel Piris-Villaespesa; Alberto Álvarez-Larrán; Adolfo Saez-Marín; Claudia Nuñez-Torrón; Gloria Muñoz-Martin; Ricardo Sánchez; Francisco J Del Castillo; Jesús Villarrubia; Javier Lopez-Jimenez; Joaquin Martinez-Lopez; Valentin Garcia-Gutierrez
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.379

6.  How Does 2016 WHO Criteria for Polycythemia Vera Contribute to Our Daily Practice? A Single-Center Study from Turkey.

Authors:  Rafet Eren; Bahar Funda Sevinçoğlu; Esma Evrim Doğan; Demet Aydın; Nihan Nizam; Naciye Demirel
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2020-10-01

7.  Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera.

Authors:  Eliane Nguyen; Michaël Harnois; Lambert Busque; Shireen Sirhan; Sarit Assouline; Ines Chamaki; Harold Olney; Luigina Mollica; Natasha Szuber
Journal:  Blood Cancer J       Date:  2021-04-15       Impact factor: 11.037

8.  Clinical Implications of Quantitative JAK2 V617F Analysis using Droplet Digital PCR in Myeloproliferative Neoplasms.

Authors:  Eunyoung Lee; Kyoung Joo Lee; Hyein Park; Jin Young Chung; Mi Na Lee; Myung Hee Chang; Jongha Yoo; Hyewon Lee; Sun Young Kong; Hyeon Seok Eom
Journal:  Ann Lab Med       Date:  2018-03       Impact factor: 3.464

9.  Eradication of Vancomycin-Resistant Enterococci by Combining Phage and Vancomycin.

Authors:  Mor Shlezinger; Shunit Coppenhagen-Glazer; Daniel Gelman; Nurit Beyth; Ronen Hazan
Journal:  Viruses       Date:  2019-10-16       Impact factor: 5.048

10.  Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN).

Authors:  Razan Hayati Zulkeflee; Zefarina Zulkafli; Muhammad Farid Johan; Azlan Husin; Md Asiful Islam; Rosline Hassan
Journal:  Int J Environ Res Public Health       Date:  2021-07-16       Impact factor: 3.390

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.